Chemistry:Amrubicin
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | IV |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C25H25NO9 |
| Molar mass | 483.473 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Amrubicin (INN; previously known as SM-5887) is an anthracycline used in the treatment of lung cancer.[1] It is marketed in Japan since 2002 by Sumitomo under the brand name Calsed.[2]
Amrubicin acts by inhibiting topoisomerase II, and has been compared in clinical trials with topotecan, a Topoisomerase I inhibitor.[3][4]
It has also been studied for the treatment of bladder carcinoma[5] and gastric cancer.[6]
Amrubicin was the first anthracycline derivative created by de novo synthesis and was first published in 1989 by scientists from Sumitomo.[7]
References
- ↑ "[New anthracycline analogues in the treatment of lung cancer]" (in ja). Gan to Kagaku Ryoho 19 (13): 2146–9. November 1992. PMID 1332624.
- ↑ Sumitomo Pharmaceuticals Co., Ltd. (2003). "CALSED for Injection (English)". http://www.e-search.ne.jp/~jpr/PDF/SUMITO17.PDF. [|permanent dead link|dead link}}]
- ↑ Celgene Corporation (2008). "Amrubicin(R) Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer". http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=1121403&highlight.
- ↑ Medical News Today (2007). "Pharmion's Amrubicin Shows Encouraging Results Compared To Standard Of Care In Second Line Treatment Of Small Cell Lung Cancer". http://www.medicalnewstoday.com/articles/73140.php.
- ↑ "[Experimental studies on intravesical instillation of SM-5887, a novel anthracycline derivative for treatment of bladder carcinoma]" (in ja). Gan to Kagaku Ryoho 23 (5): 601–6. April 1996. PMID 8678519.
- ↑ "[A phase II study of SM-5887 for advanced gastric cancer]" (in ja). Gan to Kagaku Ryoho 18 (7): 1151–4. June 1991. PMID 1647150.
- ↑ Hanada M. Amrubicin, Chapter 6 in Case Studies in Modern Drug Discovery and Development. Eds. Huang X and Aslanian RG. John Wiley & Sons, 2012 ISBN:9780470601815 P 106
 |  |
